|
1
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young RM, Shaffer AL III, Phelan JD and
Staudt LM: B-cell receptor signaling in diffuse large B-cell
lymphoma. Semin Hematol. 52:77–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised International Prognostic Index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar
|
|
4
|
Jiang Y and Melnick A: The epigenetic
basis of diffuse large B-cell lymphoma. Semin Hematol. 52:86–96.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clozel T, Yang S, Elstrom RL, Tam W,
Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B,
Scott DW, et al: Mechanism-based epigenetic chemosensitization
therapy of diffuse large B-cell lymphoma. Cancer Discov.
3:1002–1019. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaknovich R, Geng H, Johnson NA, Tsikitas
L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O and Melnick A:
DNA methylation signatures define molecular subtypes of diffuse
large B-cell lymphoma. Blood. 116:e81–e89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robaina MC, Mazzoccoli L, Arruda VO, Reis
FR, Apa AG, de Rezende LM and Klumb CE: Deregulation of DNMT1,
DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution
for disease pathogenesis. Exp Mol Pathol. 98:200–207. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao X, Yang F, Li S, Liu M, Ying S, Jia X
and Wang X: CpG island methylator phenotype of myelodysplastic
syndrome identified through genome-wide profiling of DNA
methylation and gene expression. Br J Haematol. 165:649–658. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amara K, Ziadi S, Hachana M, Soltani N,
Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein
over-expression as a prognostic factor in patients with diffuse
large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Freiss G and Chalbos D: PTPN13/PTPL1: An
important regulator of tumor aggressiveness. Anticancer Agents Med
Chem. 11:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Castilla C, Chinchón D, Medina R, Torrubia
FJ, Japón MA and Sáez C: PTPL1 and PKCδ contribute to proapoptotic
signalling in prostate cancer cells. Cell Death Dis. 4:e5762013.
View Article : Google Scholar
|
|
12
|
Glondu-Lassis M, Dromard M, Chavey C,
Puech C, Fajas L, Hendriks W and Freiss G: Downregulation of
protein tyrosine phosphatase PTP-BL represses adipogenesis. Int J
Biochem Cell Biol. 41:2173–2180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bodoor K, Haddad Y, Alkhateeb A, Al-Abbadi
A, Dowairi M, Magableh A, Bsoul N and Ghabkari A: DNA
hypermethylation of cell cycle (p15 and p16) and apoptotic (p14,
p53, DAPK and TMS1) genes in peripheral blood of leukemia patients.
Asian Pac J Cancer Prev. 15:75–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Don KR, Ramani P, Ramshankar V, Sherlin
HJ, Premkumar P and Natesan A: Promoter hypermethylation patterns
of P16, DAPK and MGMT in oral squamous cell carcinoma: A systematic
review and meta-analysis. Indian J Dent Res. 25:797–805. 2014.
View Article : Google Scholar
|
|
15
|
Kupčinskaitė-Noreikienė R, Skiecevičienė
J, Jonaitis L, Ugenskienė R, Kupčinskas J, Markelis R, Baltrėnas V,
Sakavičius L, Semakina I, Grižas S, et al: CpG island meth-ylation
of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent
noncancerous stomach tissues. Medicina (Kaunas). 49:361–366.
2013.
|
|
16
|
Zhang Z, Nie F, Kang C, Chen B, Qin Z, Ma
J, Ma Y and Zhao X: Increased periostin expression affects the
proliferation, collagen synthesis, migration and invasion of keloid
fibroblasts under hypoxic conditions. Int J Mol Med. 34:253–261.
2014.PubMed/NCBI
|
|
17
|
Liang Y, Li Z, Mo N, Li M, Zhuang Z, Wang
J, Wang Y and Guo X: Isoflurane preconditioning ameliorates renal
ischemia-reperfusion injury through antiinflammatory and
antiapoptotic actions in rats. Biol Pharm Bull. 37:1599–1605. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saleem M, Abbas K, Manan M, Ijaz H, Ahmed
B, Ali M, Hanif M, Farooqi AA and Qadir MI: Review - epigenetic
therapy for cancer. Pak J Pharm Sci. 28:1023–1032. 2015.PubMed/NCBI
|
|
19
|
Pike BL, Greiner TC, Wang X, Weisenburger
DD, Hsu YH, Renaud G, Wolfsberg TG, Kim M, Weisenberger DJ,
Siegmund KD, et al: DNA methylation profiles in diffuse large
B-cell lymphoma and their relationship to gene expression status.
Leukemia. 22:1035–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gibaja V, Shen F, Harari J, Korn J, Ruddy
D, Saenz-Vash V, Zhai H, Rejtar T, Paris CG, Yu Z, et al:
Development of secondary mutations in wild-type and mutant EZH2
alleles cooperates to confer resistance to EZH2 inhibitors.
Oncogene. Apr 20–2015.(Epub ahead of print). http://dx.doi.org/10.1038/onc.2015.114.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang S and Wang Z: Epigenetic aberrant
methylation of tumor suppressor genes in small cell lung cancer. J
Thorac Dis. 5:532–537. 2013.PubMed/NCBI
|
|
22
|
Mehta A, Dobersch S, Romero-Olmedo AJ and
Barreto G: Epige-netics in lung cancer diagnosis and therapy.
Cancer Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Witzig TE, Hu G, Offer SM, Wellik LE, Han
JJ, Stenson MJ, Dogan A, Diasio RB and Gupta M: Epigenetic
mechanisms of protein tyrosine phosphatase 6 suppression in diffuse
large B-cell lymphoma: Implications for epigenetic therapy.
Leukemia. 28:147–154. 2014. View Article : Google Scholar :
|
|
24
|
Kristensen LS, Treppendahl MB, Asmar F,
Girkov MS, Nielsen HM, Kjeldsen TE, Ralfkiaer E, Hansen LL and
Grønbæk K: Investigation of MGMT and DAPK1 methylation patterns in
diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Sci
Rep. 3:27892013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koyama M, Oka T, Ouchida M, Nakatani Y,
Nishiuchi R, Yoshino T, Hayashi K, Akagi T and Seino Y: Activated
proliferation of B-cell lymphomas/leukemias with the SHP1 gene
silencing by aberrant CpG methylation. Lab Invest. 83:1849–1858.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scarfò L and Ghia P: Reprogramming cell
death: BCL2 family inhibition in hematological malignancies.
Immunol Lett. 155:36–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta S and Knowlton AA: HSP60, Bax,
apoptosis and the heart. J Cell Mol Med. 9:51–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeng J, Chen S, Li N, Chen L, Su J, Niu G,
Zhu S and Liang Y: Sasanquasaponin from Camellia oleifera Abel.
induces apoptosis via Bcl-2, Bax and caspase-3 activation in HepG2
cells. Mol Med Rep. 12:1997–2002. 2015.PubMed/NCBI
|
|
29
|
Chang C, Swaan PW, Ngo LY, Lum PY, Patil
SD and Unadkat JD: Molecular requirements of the human nucleoside
transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol. 65:558–570.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pastor-Anglada M and Pérez-Torras S:
Nucleoside transporter proteins as biomarkers of drug
responsiveness and drug targets. Front Pharmacol. 6:132015.
View Article : Google Scholar : PubMed/NCBI
|
